Oddo BHF - Industrie Net Zéro : la Commission dévoile les technologies éligibles – les SAF et le nucléaire listés mais non prioritaires

Report

Oddo BHF

Jean-Baptiste Rouphael ...

Marc Lavaud

Industrie Net Zéro : la Commission dévoile les technologies éligibles – les SAF et le nucléaire listés mais non prioritaires

>Un plan centré sur 8 technologies « net zéro » stratégiques - La Commission Européenne a publié le 16 mars sa proposition de règlement Net Zero Industry Act. Ce plan avait été annoncé le 17 janvier dernier par Ursula Von Der Leyen au sommet de Davos, en réponse à l’IRA américain (voir notre flash ici). Ce plan est un des trois volets du « Green Deal Industriel » européen, avec la loi sur les matières premières critiques, également présentée aujourd’hui (sur ce vol...

17/03/2023 1 FR

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Jean-Baptiste Rouphael

Marc Lavaud

Other Reports from Oddo BHF

Team Pharma

Team Pharma

ODDO : The macroeconomic environment is not helping the sector

The last few weeks had seen renewed interest in the sector, with stronger volumes, M&A activity and market transactions. Unfortunately, the political context in France has again undermined French biotechs. A large number of clinical results are expected in the next few months (Ose, Aelis, Genfit, Medincell, Trangsene, Abivax, etc.). If successful, these could reinvigorate the sector. In the meantime, we are taking a more decisive stance, increasing the beta of the firms in our sa...

18m 18m 1 EN

Team Pharma

Team Pharma

ODDO : L'environnement macro ne favorise pas le secteur

Ces dernières semaines avaient laissé entrevoir un regain d’intérêt pour le secteur avec une hausse des volumes, du M&A et des opérations de marché. Malheureusement le contexte politique français vient à nouveau de pénaliser les biotechs françaises. Un nombre important de résultats cliniques sont attendus dans ces prochains mois (Ose, Aelis, Genfit, Medincell, Trangsene, Abivax…) qui pourraient, en cas de succès, redynamiser le secteur. Dans l’intervalle, nous décidons d’être plu...

1h 1h 1 FR

Nicolas David

Nicolas David

Capgemini : Europe set to undermine recovery momentum for the group

>Set for very slight improvement in growth in Q2, driven by US - Capgemini is due to report its H1 2024 results on 26 July before trading. Based on our discussions with the company and its main peers, we understand that organic growth in Q2 is set to show an improvement on Q1. However, we think it is likely to be modest. Indeed, only North America (31% of revenues) is posting tangible signs of improvement at this stage, driven by a smaller decline for the banking/fina...

2h / 12m 2h / 12m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Industrie Net Zéro : la Commission dévoile les technologies éligibles – les SAF et le nucléaire listés mais non prioritaires

ODDO : The macroeconomic environment is not helping the sector

ODDO : L'environnement macro ne favorise pas le secteur

Capgemini : Europe set to undermine recovery momentum for the group

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe